Navigation Links
Tolera Therapeutics Files IND Application for TOL101, Appoints O'Toole to Lead Clinical Operations
Date:11/3/2009

KALAMAZOO, Mich., Nov. 3 /PRNewswire/ -- Tolera Therapeutics, Inc., announced it has filed an Investigational New Drug (IND) application with the United States Food and Drug Administration (FDA) for its lead candidate, TOL101, for prophylaxis of acute rejection of solid organ transplantation. TOL101 is a novel biologic protein that is designed to safely and specifically target T cells, components of the immune system that play a key role in the rejection, and ultimate failure, of transplanted organs. Organ transplantation is often the only viable treatment for many end-stage organ diseases.

"We are extremely pleased with our progress toward bringing TOL101 to the clinic," commented John J. Puisis, President and CEO of Tolera. "This action marks an important development milestone as the company continues its drive to address the patient's need for safer and more effective immune suppression therapy. Current industry practices and pipelines offer limited and incomplete solutions to advance patient care and meet this critical need. Pending acceptance by the FDA, we intend to conduct clinical studies starting in 2010."

Tolera also announced the appointment of Leslie O'Toole to lead its clinical operations as Director, Clinical Programs. O'Toole brings over 20 years of industry experience with 16 years focusing on clinical research management. Mr. Puisis added "We're excited about adding Leslie to our dynamic team. Her depth of clinical research experience adds an important operating aspect to the organization and positions us for continued success." Prior to joining the company, O'Toole was Director, Project Management at Clinimetrics, a full service contract research organization where she was involved in over 35 studies researching drugs in numerous indications with a primary focus in oncology and immunology.

About Tolera Therapeutics: Tolera Therapeutics is a Kalamazoo, Michigan based biotechnology company and a spin-off of the Cleveland Clinic Foundation. Primary investors in the company include Southwest Michigan First Life Sciences Fund, Triathlon Medical Venture Partners, Hopen Therapeutics and the Michigan Economic Development Corporation. Building upon research done at the University of Kentucky and the Cleveland Clinic, Tolera Therapeutics is developing and commercializing therapies for the immune modulation market with the goal of addressing unmet medical needs with safer, more targeted solutions to reduce the risk of serious and toxic side effects often associated with immunotherapy. The company is focusing on commercializing therapeutic monoclonal antibody technology for the transplantation and autoimmune markets. Additional information concerning the company and its technology can be found on its website www.tolera.com.

SOURCE Tolera Therapeutics, Inc.


'/>"/>
SOURCE Tolera Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
3. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
4. Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer
5. Hepatitis B Foundation and AAPCHO Sponsor Congressional Briefing on Zero Tolerance for Hepatitis B
6. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
7. Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated
8. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
9. Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
10. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
11. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... Led by industry ... science products comes to New Orleans, Philadelphia and San Diego in 2017. The ... America and discuss local cultural nuances for working with the regulators. , This ...
(Date:4/28/2017)... Westlake Village, CA (PRWEB) , ... April 28, 2017 , ... ... diagnostics, today announced the launch of a new neoadjuvant breast cancer monitoring (NEAT) study ... include at least 10 centers and over 150 patients to be monitored over two ...
(Date:4/28/2017)... IL (PRWEB) , ... April 28, 2017 , ... While ... worked hard to restructure the company and provide a new outlook for the future. ... has decided to implement new management with the retirement of Mr. Siegel as CEO. ...
(Date:4/28/2017)... Kansas City, KS. (PRWEB) , ... April 28, ... ... functional service contract research organization (CRO) has validated a 0.2 ng/mL lower limit ... Previously having validated a 0.5 ng/mL LLOQ assay, the ultra-low trace nicotine assay ...
Breaking Biology Technology:
(Date:4/24/2017)... -- Janice Kephart , former 9/11 Commission ... LLP (IdSP) , today issues the following statement: ... 6, 2017 Executive Order: Protecting the Nation ... instilled with greater confidence, enabling the reactivation of ... are suspended by until at least July 2017). ...
(Date:4/19/2017)... 19, 2017 The global military ... is marked by the presence of several large global ... by five major players - 3M Cogent, NEC Corporation, ... for nearly 61% of the global military biometric market ... the global military biometrics market boast global presence, which ...
(Date:4/18/2017)... Inc., a global expert in SoC-based imaging and computing solutions, has ... features the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® ... be showcased during the upcoming Medtec Japan at Tokyo Big Sight ... Las Vegas Convention Center April 24-27. ... Click here for an image of the ...
Breaking Biology News(10 mins):